Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors
Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors
复制标题
硫酸长春碱治疗转移性尿路上皮肿瘤的 II 期试验
DOI：
10.1002/1097-0142(19820801)50:3
复制
发表时间：
1982
期刊：
影响因子：
6.2
通讯作者：
R. Watson
中科院分区：
文献类型：
--
作者：
M. Blumenreich;A. Yagoda;R. Natale;R. Watson
Vinblastine sulfate, 0.10–0.15 mg/kg IV every week, was given to 37 patients with bidimensionally measurable, metastatic transitional cell carcinoma of the urothelial tract. Twenty‐eight patients, the majority of whom had received extensive prior chemotherapy, had an adequate trial and five (18%; 95% confidence limits, 3–33%) achieved a partial remission (>50% decrease in tumor size) of 2–5 months' duration. Responding sites included lung and nodal metastases. Toxicity, primarily leukopenia, was mild to moderate. The 18% response rate obtained in heavily pretreated cases suggests that vinblastine sulfate has some efficacy in the treatment of patients with advanced urothelial tract tumors.
